Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NovaBay Pharmaceuticals Inc (NBY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: NBY (3-star) is a STRONG-BUY. BUY since 80 days. Simulated Profits (294.37%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.85
1 Year Target Price $0.85
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 91.65% | Avg. Invested days 42 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 352.83M USD | Price to earnings Ratio 0.54 | 1Y Target Price 0.85 |
Price to earnings Ratio 0.54 | 1Y Target Price 0.85 | ||
Volume (30-day avg) 1 | Beta 0.48 | 52 Weeks Range 0.30 - 3.00 | Updated Date 12/13/2025 |
52 Weeks Range 0.30 - 3.00 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 31.48% | Operating Margin (TTM) -224.38% |
Management Effectiveness
Return on Assets (TTM) -86.98% | Return on Equity (TTM) -516.26% |
Valuation
Trailing PE 0.54 | Forward PE - | Enterprise Value 355283097 | Price to Sales(TTM) 34.25 |
Enterprise Value 355283097 | Price to Sales(TTM) 34.25 | ||
Enterprise Value to Revenue 34.49 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 126010749 | Shares Floating 12393157 |
Shares Outstanding 126010749 | Shares Floating 12393157 | ||
Percent Insiders - | Percent Institutions 0.99 |
About NovaBay Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2007-10-26 | CEO & Director Michael Kazley | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://novabay.com |
Full time employees 13 | Website https://novabay.com | ||
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products. The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions. It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.